arrow_back Back Filing freshness 10-Q Q2 FY2026 SEC EDGAR

download Export Data

enGene Therapeutics Inc.

ENGN

$1.79 ▼ -0.01 (-0.56%) at close

16 Visible periods

23 Metrics

Peer-ranked Benchmarks

Price Chart

Health

Poor

Bearish

auto_awesome

Analytical Summary

enGene Therapeutics Inc. faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $124.8M

Dividend Yield —

Revenue Growth —

Op. Margin —

ROIC -12.5% ↘

FCF / Share $-0.44 →

Trailing P/E —

Price / Book 0.5x

FCF Yield —

Debt / Equity —

info Valuation on last close. End-of-day price, Aug 7, 2026.

16-Year Financial Trajectory

Quarterly

Metric Value Trend Year over Year Percentile

Net Income Profit after all expenses

$-29.75M

↓ -20.9% —

FCF / Share Free cash flow per share

$-0.44

↓ -1.6% —

trending_up

Bullish Indicators

No bullish signals detected.

warning

Bearish Risks

Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns

Financial Health ↓

Cash Quality ↑

Dividend History

Dividend / share · sourced from SEC filings

$0.00 Latest / share

FY 2021

FY 2022

$0.00

FY 2023

$0.00

FY 2024

$0.00

FY 2025

Financial view

Statement lens

Choose the reporting cadence, isolate a period range, or search directly for a metric.

Cadence

Annual Quarterly

Range

→

📈 Is growth accelerating? 4 metrics

Metric	Q2 FY2026 Apr 30, 2026 10-Q ↗	Q1 FY2026 Jan 31, 2026 10-Q ↗	Q4 FY2025 Oct 31, 2025 10-K ↗	Q3 FY2025 Jul 31, 2025 10-Q ↗	Q2 FY2025 Apr 30, 2025 10-Q ↗	Q1 FY2025 Jan 31, 2025 10-Q ↗	Q4 FY2024 Oct 31, 2024 10-K ↗	Q3 FY2024 Jul 31, 2024 10-Q ↗	Q2 FY2024 Apr 30, 2024 10-Q ↗	Q1 FY2024 Jan 31, 2024 10-Q ↗	Q4 FY2023 Oct 31, 2023 10-K ↗	Q3 FY2023 Jul 31, 2023 10-Q ↗	Q2 FY2023 Apr 30, 2023 10-Q ↗	Q1 FY2023 Jan 31, 2023 10-Q ↗	Q4 FY2022 Oct 31, 2022 10-K ↗	Q4 FY2021 Oct 31, 2021 10-K ↗
EPS Growth YoY (%)	N/M	-8.3% Weak ↓ Weak Declining Year-over-year change in earnings per share Optimal: > 10%	114.7% Excellent ↑ Excellent Improving Year-over-year change in earnings per share Optimal: > 10%	78.1% Excellent ↑ Excellent Improving Year-over-year change in earnings per share Optimal: > 10%	34.2% Excellent ↑ Excellent Improving Year-over-year change in earnings per share Optimal: > 10%	4.3% Caution ↑ Caution Improving Year-over-year change in earnings per share Optimal: > 10%	-99.7% Weak → Weak Stable Year-over-year change in earnings per share Optimal: > 10%	-96.3% Weak → Weak Stable Year-over-year change in earnings per share Optimal: > 10%	-95.9% Weak Weak Year-over-year change in earnings per share Optimal: > 10%	-96.5% Weak Weak Year-over-year change in earnings per share Optimal: > 10%	—	—	—	—	—	—
Net Income Growth YoY (%)	-20.9% Weak ↑ Weak Improving Year-over-year change in net income	-20.9% Weak ↑ Weak Improving Year-over-year change in net income	-147.6% Weak ↓ Weak Declining Year-over-year change in net income	-129.8% Weak ↓ Weak Declining Year-over-year change in net income	-129.8% Weak ↓ Weak Declining Year-over-year change in net income	-129.8% Weak ↓ Weak Declining Year-over-year change in net income	81.5% Excellent ↑ Excellent Improving Year-over-year change in net income	-44.4% Weak → Weak Stable Year-over-year change in net income	-44.4% Weak Weak Year-over-year change in net income	-44.4% Weak Weak Year-over-year change in net income	—	—	—	—	—	—
FCF Growth YoY (%)	—	15.3% Good Good Year-over-year change in free cash flow	—	—	—	-50.2% Weak Weak Year-over-year change in free cash flow	—	—	—	96.5% Excellent Excellent Year-over-year change in free cash flow	—	—	—	—	—	—
EPS CAGR 3Y (%)	—	-67.9% Weak Weak Compound annual EPS growth over 3 years	—	—	—	—	—	—	—	—	—	—	—	—	—	—

💰 Are margins durable? 2 metrics

Metric	Q2 FY2026 Apr 30, 2026 10-Q ↗	Q1 FY2026 Jan 31, 2026 10-Q ↗	Q4 FY2025 Oct 31, 2025 10-K ↗	Q3 FY2025 Jul 31, 2025 10-Q ↗	Q2 FY2025 Apr 30, 2025 10-Q ↗	Q1 FY2025 Jan 31, 2025 10-Q ↗	Q4 FY2024 Oct 31, 2024 10-K ↗	Q3 FY2024 Jul 31, 2024 10-Q ↗	Q2 FY2024 Apr 30, 2024 10-Q ↗	Q1 FY2024 Jan 31, 2024 10-Q ↗	Q4 FY2023 Oct 31, 2023 10-K ↗	Q3 FY2023 Jul 31, 2023 10-Q ↗	Q2 FY2023 Apr 30, 2023 10-Q ↗	Q1 FY2023 Jan 31, 2023 10-Q ↗	Q4 FY2022 Oct 31, 2022 10-K ↗	Q4 FY2021 Oct 31, 2021 10-K ↗
Effective Tax Rate (%) (%)	0.0% Excellent ↓ Excellent Declining Actual taxes paid relative to pre-tax income Optimal: 15-25%	0.0% Excellent ↑ Excellent Improving Actual taxes paid relative to pre-tax income Optimal: 15-25%	1.3% Excellent ↑ Excellent Improving Actual taxes paid relative to pre-tax income Optimal: 15-25%	-0.8% Excellent ↓ Excellent Declining Actual taxes paid relative to pre-tax income Optimal: 15-25%	-0.9% Excellent ↓ Excellent Declining Actual taxes paid relative to pre-tax income Optimal: 15-25%	-0.1% Excellent ↓ Excellent Declining Actual taxes paid relative to pre-tax income Optimal: 15-25%	-0.1% Excellent ↓ Excellent Declining Actual taxes paid relative to pre-tax income Optimal: 15-25%	0.2% Excellent ↑ Excellent Improving Actual taxes paid relative to pre-tax income Optimal: 15-25%	-0.1% Excellent ↓ Excellent Declining Actual taxes paid relative to pre-tax income Optimal: 15-25%	0.3% Excellent ↑ Excellent Improving Actual taxes paid relative to pre-tax income Optimal: 15-25%	-0.0% Excellent → Excellent Stable Actual taxes paid relative to pre-tax income Optimal: 15-25%	0.0% Excellent → Excellent Stable Actual taxes paid relative to pre-tax income Optimal: 15-25%	0.0% Excellent Excellent Actual taxes paid relative to pre-tax income Optimal: 15-25%	0.0% Excellent Excellent Actual taxes paid relative to pre-tax income Optimal: 15-25%	—	—
FCF / Net Income (x)	1.03x Fair ↑ Fair Improving Free cash flow relative to reported net income Optimal: > 1x	0.98x Caution ↑ Caution Improving Free cash flow relative to reported net income Optimal: > 1x	0.67x Weak ↓ Weak Declining Free cash flow relative to reported net income Optimal: > 1x	1.07x Fair ↓ Fair Declining Free cash flow relative to reported net income Optimal: > 1x	—	1.06x Fair Fair Free cash flow relative to reported net income Optimal: > 1x	1.29x Good Good Free cash flow relative to reported net income Optimal: > 1x	—	—	0.74x Caution ↑ Caution Improving Free cash flow relative to reported net income Optimal: > 1x	0.08x Weak ↓ Weak Declining Free cash flow relative to reported net income Optimal: > 1x	1.01x Fair ↑ Fair Improving Free cash flow relative to reported net income Optimal: > 1x	0.60x Weak Weak Free cash flow relative to reported net income Optimal: > 1x	0.84x Caution Caution Free cash flow relative to reported net income Optimal: > 1x	—	—

🎯 Is capital allocation efficient? 3 metrics

Metric	Q2 FY2026 Apr 30, 2026 10-Q ↗	Q1 FY2026 Jan 31, 2026 10-Q ↗	Q4 FY2025 Oct 31, 2025 10-K ↗	Q3 FY2025 Jul 31, 2025 10-Q ↗	Q2 FY2025 Apr 30, 2025 10-Q ↗	Q1 FY2025 Jan 31, 2025 10-Q ↗	Q4 FY2024 Oct 31, 2024 10-K ↗	Q3 FY2024 Jul 31, 2024 10-Q ↗	Q2 FY2024 Apr 30, 2024 10-Q ↗	Q1 FY2024 Jan 31, 2024 10-Q ↗	Q4 FY2023 Oct 31, 2023 10-K ↗	Q3 FY2023 Jul 31, 2023 10-Q ↗	Q2 FY2023 Apr 30, 2023 10-Q ↗	Q1 FY2023 Jan 31, 2023 10-Q ↗	Q4 FY2022 Oct 31, 2022 10-K ↗	Q4 FY2021 Oct 31, 2021 10-K ↗
Return on Invested Capital (%)	-12.5% Weak ↑ Weak Improving Return earned on debt + equity capital invested Optimal: > 10%	-11.1% Weak ↑ Weak Improving Return earned on debt + equity capital invested Optimal: > 10%	-23.2% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-15.0% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-12.0% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-10.7% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-6.4% Weak ↑ Weak Improving Return earned on debt + equity capital invested Optimal: > 10%	-7.3% Weak ↑ Weak Improving Return earned on debt + equity capital invested Optimal: > 10%	-7.1% Weak ↑ Weak Improving Return earned on debt + equity capital invested Optimal: > 10%	-17.2% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-14.4% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	6.7% Caution ↑ Caution Improving Return earned on debt + equity capital invested Optimal: > 10%	5.3% Caution Caution Return earned on debt + equity capital invested Optimal: > 10%	5.5% Caution Caution Return earned on debt + equity capital invested Optimal: > 10%	—	—
Return on Capital (%) (%)	-10.4% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-9.3% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-17.8% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-12.2% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-10.2% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-9.3% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-5.6% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-6.3% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-6.3% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-11.5% Weak Weak Operating profit relative to total assets Optimal: > 10%	-12.0% Weak Weak Operating profit relative to total assets Optimal: > 10%	—	—	—	—	—
Return on Common Equity (%) (%)	-11.7% Weak ↑ Weak Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-178%)	-10.6% Weak ↑ Weak Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-170%)	-22.6% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-251%)	-12.3% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-182%)	-10.8% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-172%)	-9.8% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-166%)	-5.6% Weak ↑ Weak Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-137%)	-4.7% Weak ↑ Weak Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-131%)	-4.4% Weak ↑ Weak Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-129%)	-17.2% Weak ↑ Weak Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-214%)	-113.8% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-859%)	7.9% Caution ↓ Caution Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-47%)	8.3% Caution Caution Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-45%)	8.8% Caution Caution Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-41%)	—	—

⚖️ Is the balance sheet risky? 2 metrics

Metric	Q2 FY2026 Apr 30, 2026 10-Q ↗	Q1 FY2026 Jan 31, 2026 10-Q ↗	Q4 FY2025 Oct 31, 2025 10-K ↗	Q3 FY2025 Jul 31, 2025 10-Q ↗	Q2 FY2025 Apr 30, 2025 10-Q ↗	Q1 FY2025 Jan 31, 2025 10-Q ↗	Q4 FY2024 Oct 31, 2024 10-K ↗	Q3 FY2024 Jul 31, 2024 10-Q ↗	Q2 FY2024 Apr 30, 2024 10-Q ↗	Q1 FY2024 Jan 31, 2024 10-Q ↗	Q4 FY2023 Oct 31, 2023 10-K ↗	Q3 FY2023 Jul 31, 2023 10-Q ↗	Q2 FY2023 Apr 30, 2023 10-Q ↗	Q1 FY2023 Jan 31, 2023 10-Q ↗	Q4 FY2022 Oct 31, 2022 10-K ↗	Q4 FY2021 Oct 31, 2021 10-K ↗
Interest Coverage (x)	-70.11x Weak ↓ Weak Declining Operating income divided by interest expense Optimal: > 5x	-57.33x Weak → Weak Stable Operating income divided by interest expense Optimal: > 5x	-55.53x Weak → Weak Stable Operating income divided by interest expense Optimal: > 5x	-56.29x Weak ↓ Weak Declining Operating income divided by interest expense Optimal: > 5x	—	-50.02x Weak ↓ Weak Declining Operating income divided by interest expense Optimal: > 5x	-32.81x Weak ↓ Weak Declining Operating income divided by interest expense Optimal: > 5x	—	-23.78x Weak ↓ Weak Declining Operating income divided by interest expense Optimal: > 5x	-19.13x Weak ↓ Weak Declining Operating income divided by interest expense Optimal: > 5x	-22.85x Weak ↓ Weak Declining Operating income divided by interest expense Optimal: > 5x	-23.58x Weak ↓ Weak Declining Operating income divided by interest expense Optimal: > 5x	-4.02x Weak Weak Operating income divided by interest expense Optimal: > 5x	-3.94x Weak Weak Operating income divided by interest expense Optimal: > 5x	—	—
Net Debt (USD)	$-29.83M	$-36.61M	$-50.15M	$-32.62M	$-57.55M	$-62.35M	$-173.00M	$-257.68M	$-264.81M	$-85.65M	$-81.52M	—	—	—	$-20.43M	—

📊 What does each share earn? 7 metrics

Metric	Q2 FY2026 Apr 30, 2026 10-Q ↗	Q1 FY2026 Jan 31, 2026 10-Q ↗	Q4 FY2025 Oct 31, 2025 10-K ↗	Q3 FY2025 Jul 31, 2025 10-Q ↗	Q2 FY2025 Apr 30, 2025 10-Q ↗	Q1 FY2025 Jan 31, 2025 10-Q ↗	Q4 FY2024 Oct 31, 2024 10-K ↗	Q3 FY2024 Jul 31, 2024 10-Q ↗	Q2 FY2024 Apr 30, 2024 10-Q ↗	Q1 FY2024 Jan 31, 2024 10-Q ↗	Q4 FY2023 Oct 31, 2023 10-K ↗	Q3 FY2023 Jul 31, 2023 10-Q ↗	Q2 FY2023 Apr 30, 2023 10-Q ↗	Q1 FY2023 Jan 31, 2023 10-Q ↗	Q4 FY2022 Oct 31, 2022 10-K ↗	Q4 FY2021 Oct 31, 2021 10-K ↗
Basic EPS, GAAP (USD)	$-0.43	$0.44	$0.73	$0.57	$0.51	$0.48	$0.34	$0.32	$0.38	$0.46	$120.45	$8.55	$9.30	$13.29	—	—
Free Cash Flow per Share (USD)	$-0.44	$-0.43	—	$-0.52	—	$-0.51	—	—	—	$-0.34	—	$-10.63	$-6.41	$-9.58	—	—
Dividend per Share (USD)	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	—	—	—	$0.00	—	—	—	—	—	—
Book Value per Share (USD)	$3.81	$4.20	$3.22	$3.93	$4.45	$4.90	$5.35	$5.21	$5.50	$2.69	$3.12	$-133.92	$-128.49	$-129.04	$-115.08	—
Tangible Book Value per Share (USD)	$3.81	$4.20	$3.22	$3.93	$4.45	$4.90	$5.35	$5.21	$5.50	$2.69	$3.12	$-133.92	$-128.49	$-129.04	$-115.08	—
Basic Weighted Avg Shares (shares)	69.72M	67.26M	—	51.10M	51.02M	50.98M	—	44.17M	39.44M	23.20M	—	701,323	694,497	651,074	—	—
Dividend Payout Ratio (%)	0.0% Excellent → Excellent Stable Dividends paid as a percentage of earnings Optimal: 30-60%	0.0% Excellent → Excellent Stable Dividends paid as a percentage of earnings Optimal: 30-60%	0.0% Excellent → Excellent Stable Dividends paid as a percentage of earnings Optimal: 30-60%	0.0% Excellent → Excellent Stable Dividends paid as a percentage of earnings Optimal: 30-60%	0.0% Excellent Excellent Dividends paid as a percentage of earnings Optimal: 30-60%	0.0% Excellent Excellent Dividends paid as a percentage of earnings Optimal: 30-60%	—	—	—	—	—	—	—	—	—	—

🏦 How resilient is the balance sheet? 2 metrics

Metric	Q2 FY2026 Apr 30, 2026 10-Q ↗	Q1 FY2026 Jan 31, 2026 10-Q ↗	Q4 FY2025 Oct 31, 2025 10-K ↗	Q3 FY2025 Jul 31, 2025 10-Q ↗	Q2 FY2025 Apr 30, 2025 10-Q ↗	Q1 FY2025 Jan 31, 2025 10-Q ↗	Q4 FY2024 Oct 31, 2024 10-K ↗	Q3 FY2024 Jul 31, 2024 10-Q ↗	Q2 FY2024 Apr 30, 2024 10-Q ↗	Q1 FY2024 Jan 31, 2024 10-Q ↗	Q4 FY2023 Oct 31, 2023 10-K ↗	Q3 FY2023 Jul 31, 2023 10-Q ↗	Q2 FY2023 Apr 30, 2023 10-Q ↗	Q1 FY2023 Jan 31, 2023 10-Q ↗	Q4 FY2022 Oct 31, 2022 10-K ↗	Q4 FY2021 Oct 31, 2021 10-K ↗
Working Capital (USD)	$248.51M	$264.61M	$169.41M	$190.87M	$209.97M	$209.37M	$232.70M	$249.24M	$263.31M	$82.67M	$80.18M	—	—	—	$17.48M	—
Total Equity (USD)	$255.17M	$281.55M	$167.71M	$200.67M	$227.29M	$249.95M	$272.61M	$230.33M	$242.97M	$62.38M	$72.49M	$-93.92M	$-89.24M	$-84.01M	$-76.61M	$-53.44M

📋 What is driving earnings? 3 metrics

Metric	Q2 FY2026 Apr 30, 2026 10-Q ↗	Q1 FY2026 Jan 31, 2026 10-Q ↗	Q4 FY2025 Oct 31, 2025 10-K ↗	Q3 FY2025 Jul 31, 2025 10-Q ↗	Q2 FY2025 Apr 30, 2025 10-Q ↗	Q1 FY2025 Jan 31, 2025 10-Q ↗	Q4 FY2024 Oct 31, 2024 10-K ↗	Q3 FY2024 Jul 31, 2024 10-Q ↗	Q2 FY2024 Apr 30, 2024 10-Q ↗	Q1 FY2024 Jan 31, 2024 10-Q ↗	Q4 FY2023 Oct 31, 2023 10-K ↗	Q3 FY2023 Jul 31, 2023 10-Q ↗	Q2 FY2023 Apr 30, 2023 10-Q ↗	Q1 FY2023 Jan 31, 2023 10-Q ↗	Q4 FY2022 Oct 31, 2022 10-K ↗	Q4 FY2021 Oct 31, 2021 10-K ↗
Depreciation Expense (USD)	$200.00K	$189.00K	$200.00K	$100.00K	$100.00K	$102.00K	$100.00K	$82.00K	$78.00K	$80.00K	$74.00K	$43.00K	$37.00K	$46.00K	—	—
Net Income, GAAP (USD)	$-29.75M	$-29.75M	$-37.88M	$-24.62M	$-24.62M	$-24.62M	$-15.30M	$-10.71M	$-10.71M	$-10.71M	$-82.50M	$-7.42M	$-7.42M	$-7.42M	—	—
Operating Cash Flow (USD)	$-30.50M	$-28.90M	$-24.96M	$-25.63M	—	$-25.70M	$-19.57M	—	—	$-7.37M	$-6.78M	$-7.30M	$-4.44M	$-6.22M	—	—

⌨️ Keyboard Shortcuts

/ Search

Esc Clear

A Annual

Q Quarterly

1-7 Jump to category

R Reset

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 5 years · 16 quarters

enGene Therapeutics Inc.

Analytical Summary

16-Year Financial Trajectory

Bullish Indicators

Bearish Risks

Health Breakdown

Dividend History

Statement lens

Benchmark Lens

Signals

Percentile Rankings

Peer Comparison

Compare ENGN with peers